title: [Pharmacokinetic and pharmacodynamic characteristics of berberine and jateorhizine in Coptidis Rhizoma powder and their monomeric compounds in type 2 diabetic rats].
abstract: This article focused on a comparative analysis on the pharmacokinetic and pharmacodynamic characteristics of berberine (BER) and jateorhizine(JAT) in Coptidis Rhizoma powder (HL-P) and their monomeric compounds (BER + JAT, BJ) in type 2 diabetic (T2D) rats to explore the beneficial. effect of HL-P in the treatment of T2D. The T2D rats were treated with HL-P, BER, JAT and BJ, respectively for 63 d. The pharmacokinetic parameters, dynamic changes in blood glucose level and blood lipid values were measured. The results showed that, compared with other corresponding group, t(max), T(½ka) of BER and JAT in HL-P group were reduced, while C(max), AUC(inf), AUC(last), V(L)/F were significantly increased; compared with model group, blood glucose levels were decreased significantly in HL-P group since the 18th day, while those in BER or BJ group were reduced since the 36th day, however, blood glucose levels showed no obvious changes in JAT group; compared with model group, FFA values in all treatment group were decreased significantly. Moreover, TG, HDL and LDL value in HL-P group, LDL value in BER group and HDL value in BJ group were improved significantly. The above results showed that Coptidis Rhizoma powder showed excellent pharmacokinetic characteristics and excellent activity of lowering blood glucose and lipid. It provided a scientific basis for oral application of Coptidis Rhizoma powder in the treatment of T2D.
authors.forename: Shi-chao
authors.initials: SC
authors.lastname: Wei
authors.forename: Li-jun
authors.initials: LJ
authors.lastname: Xu
authors.forename: Xin
authors.initials: X
authors.lastname: Zou
authors.forename: Jing-bin
authors.initials: JB
authors.lastname: Li
authors.forename: Shu-jun
authors.initials: SJ
authors.lastname: Jiang
authors.forename: Xiao-hu
authors.initials: XH
authors.lastname: Xu
authors.forename: Rui
authors.initials: R
authors.lastname: Huang
authors.forename: Fu-er
authors.initials: FE
authors.lastname: Lu
mesh_terms: D000818:Animals; D001599:Berberine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001786:Blood Glucose / Q000378:metabolism; D039323:Coptis / Q000737:chemistry*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D011208:Powders / Q000008:administration & dosage / Q000493:pharmacokinetics; D051381:Rats; D017208:Rats, Wistar
chemical_list: D001786:Blood Glucose; D004365:Drugs, Chinese Herbal; D011208:Powders; D001599:Berberine